{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=15", "query": { "condition": "Cancer of the Stomach", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 951, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T20:09:56.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03221426", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1007, "start_date": "2017-10-09", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 14, "location_summary": "Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03221426" }, { "nct_id": "NCT05038254", "title": "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Small Intestinal Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Pancreatic Carcinoma", "Metastatic Rectal Carcinoma", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2021-05-12", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038254" }, { "nct_id": "NCT05166577", "title": "Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma", "EBV-Related Gastric Carcinoma", "EBV-Related Leiomyosarcoma", "EBV Related Carcinoma", "EBV-Related Sarcoma" ], "interventions": [ { "name": "Nanatinostat", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viracta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-10-08", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 3, "location_summary": "Stanford, California • Aurora, Colorado • Houston, Texas", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05166577" }, { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" }, { "nct_id": "NCT00094003", "title": "Study of NS-9 in Patients With Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Neoplasms", "Neoplasm Metastasis", "Local Neoplasm Recurrences" ], "interventions": [ { "name": "NS-9 [Poly I: Poly C]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NS Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-11-11", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Houston, Texas", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094003" }, { "nct_id": "NCT03330561", "title": "PRS-343 in HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Bladder Cancer", "HER2-positive Solid Tumor" ], "interventions": [ { "name": "PRS-343", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2017-09-13", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 10, "location_summary": "Tucson, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330561" }, { "nct_id": "NCT00022139", "title": "Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2002-01", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 35, "location_summary": "Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more", "locations": [ { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" }, { "city": "El Dorado", "state": "Kansas" }, { "city": "Kingman", "state": "Kansas" }, { "city": "Liberal", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022139" }, { "nct_id": "NCT05365581", "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP2138", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2022-06-07", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 13, "location_summary": "Orange, California • Santa Monica, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05365581" }, { "nct_id": "NCT00848783", "title": "Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2008-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848783" }, { "nct_id": "NCT02197351", "title": "Narrow Band Imaging for Gastric Neoplasia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastric Cancer", "Gastric Metaplasia", "Gastric Dysplasia" ], "interventions": [ { "name": "White light biopsy", "type": "PROCEDURE" }, { "name": "Protocolled", "type": "PROCEDURE" }, { "name": "Narrow Band Imaging Guided Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2014-07", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-10-21T20:09:56.366Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197351" } ] }